Physician profile
Mary Casebolt
NPI 1588933774
$5,298.70
in general payments reported to CMS, 2019-2025
32 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $819 · 2023: $858 · 2024: $1,217 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $913.85 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $813.48 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $421.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $397.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $310.01 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $242.62 | 2023-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.05 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $224.38 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $223.08 | 2021-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.99 | 2025 | Caplyta |
| Pfizer INC. | $144.45 | 2021-2025 | |
| Galderma Laboratories, L.P. | $128.49 | 2021 | |
| Sunovion Pharmaceuticals INC. | $125.82 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $117.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.53 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.47 | 2021-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $97.34 | 2022-2025 | Gvoke Hypopen |
| Amgen INC. | $73.43 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $66.77 | 2022-2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $63.70 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $59.75 | 2024-2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $49.14 | 2022-2023 | Oxlumo |
| Edwards Lifesciences Corporation | $40.69 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $31.50 | 2021-2024 | |
| Tactile Systems Technology INC | $30.88 | 2025 | Flexitouch Plus, Nimbl |
| Teva Pharmaceuticals USA, INC. | $29.46 | 2023-2025 | Austedo Xr, Austedo Xr |
| Viatris Specialty LLC | $25.24 | 2025 | Yupelri |
| Neurocrine Biosciences, INC. | $19.77 | 2025 | |
| Sun Pharmaceutical Industries INC. | $17.11 | 2021 | |
| Amarin Pharma, INC. | $16.33 | 2021 | |
| Genentech USA, INC. | $12.42 | 2021 | |
| Depuy Synthes Sales INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Casebolt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.